A man with a rare form of blood cancer has travelled 10,000 miles to meet the stranger who saved his life. Luke Melling, 31, ...

R&D spending across the global pharmaceutical sector climbed 1.5% in 2024, according to unreleased data from Evaluate Pharma.

This advancement marks a significant step towards localising biopharmaceutical industries, reinforcing the UAE’s position as a regional hub for cellular therapies and medical innovation, ...

Explore the controversial implications of Roundup and glyphosate in American agriculture amid political and scientific ...

CompanyOverview\|NYSE:PFE] A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. (NYSE: PFE) certainly catches the eye of income- ...

Delta, a global leader in power management and smart green solutions, today unveiled its comprehensive solutions for the AI era with a focus on sustainability under the theme "Artificial Intelligence ...

With the Philadelphia Phillies adjusting to life without the suspended José Alvarado, could veteran reliever Liam Hendriks, ...

The least absolute shrinkage and selection operator-logistic regression (Lasso-LR) model is optimal for predicting ...

The outcome of patients with mantle cell lymphoma (MCL) has largely improved over the past decades. 1-3 The introduction of rituximab and the use of high-dose cytarabine followed by stem-cell rescue ...

The ALCL-Relapse study was designed by the European Inter-Group for Childhood Non-Hodgkin Lymphoma as a prospective, stratified, multinational clinical trial and was opened for patients at trial sites ...

At the second attempt, the FDA has approved Citius Pharmaceuticals' marketing application for Lymphir, a new version of a lymphoma therapy withdrawn from sale several years ago. The US regulator ...

Bristol-Myer Squibb has only just won FDA approval for its CAR-T Breyanzi in large B-cell lymphoma (LBCL), but is already eyeing an expansion into earlier-line therapy that could overtake rival ...